aef0217
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2021 (NCT05170737)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cannabinoid CB1 receptorANTAGONIST
CNR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05748405 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2022 | Aelis Farma, European Commission, Fundació IMIM - Parc de Salut Mar |
| NCT05170737 | Phase 1 | Oct 1, 2021 | Aelis Farma, European Commission, Fundació IMIM - Parc de Salut Mar |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aelis Farma | For profit | 2 | 2 | 2 | 2021 |
| European Commission | Government | 2 | 0 | 2 | 2021 |
| Fundació IMIM - Parc de Salut Mar | Academic/Hospital | 2 | 0 | 2 | 2021 |
3 organizations
Page 1 / 1